ORAL CONTRACEPTIVE AND HORMONE REPLACEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS

本研究的总体目标是解决 外源性女性激素对患者疾病活动性和严重程度的影响 系统性红斑狼疮（SLE），一种主要影响 少数民族妇女。 口服避孕药和雌激素替代品 一般不规定，因为人们普遍认为， 激活SLE。 然而，这种普遍接受的做法仅仅是基于 关于女性性别的主导地位、雌激素的生物学异常 代谢，狼疮的小鼠模型，一些病人的轶事， 在接受外源性激素时疾病发作， 在既存肾脏疾病患者中进行的研究。 相比之下， 最近的一项回顾性研究表明，耀斑的发生率不是 在服用口服避孕药的患者中统计学增加。 的 先前存在的数据不足以保证解雇一名 在一种疾病中潜在的重要节育选择， 主要影响育龄妇女， 生育能力不会因疾病而明显改变。 此外，使用 合成雌激素来保持服用 环磷酰胺和使用雌激素预防绝经后和 类固醇引起的骨质疏松症是及时的考虑。

The overall goal of the current study is to address the effect of exogenous female hormones on disease activity and severity in patients with systemic lupus erythematosus (SLE), a disease which largely affects minority women. Oral contraceptives and estrogen replacement are generally not prescribed due to the widely held view that they can activate SLE. However, this generally accepted practice is based only on the predominance of female gender, biologic abnormalities of estrogen metabolism, murine models of lupus, several anecdotes of patients having disease flares while receiving exogenous hormones, and one retrospective study in patients with pre-existing renal disease. In contrast, a more recent retrospective study suggests that the rate of flare is not statistically increased in patients taking oral contraceptives. The pre-existing data are insufficient to warrant the dismissal of a potentially important birth control option in a disease which predominantly affects women in their reproductive years and whose fertility is not appreciably altered by the disease. Moreover, the use of synthetic estrogens to preserve fertility in patients taking cyclophosphamide and the use of estrogens to prevent post-menopausal and steroid induced osteoporosis are timely considerations.